Heron Therapeutics | HRTX - Sales Revenues


Heron Therapeutics reported $40.59M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Surmodics USD 29.57M 355K Jun/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025